Compare GSK plc (GSK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs 10X Genomics Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: GSK plc is far larger — about 9.1× 10X Genomics Inc's market cap, and GSK plc pays a 3.9% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and 10X Genomics Inc for 91 Days on average.
| GSK | TXG | |
|---|---|---|
Market Cap | $91.88B | $10.07B |
Volume | 7,730,529 | 5,657,286 |
Sector | Health | Health |
52-Week High | $61.18 | $97.74 |
52-Week Low | $43.24 | $11.48 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $111.88B | $9.59B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
